Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 2
2004 2
2005 4
2006 3
2007 2
2008 10
2009 7
2010 8
2011 10
2012 12
2013 20
2014 11
2015 17
2016 21
2017 15
2018 15
2019 23
2020 34
2021 34
2022 43
2023 31
2024 19

Text availability

Article attribute

Article type

Publication date

Search Results

315 results

Results by year

Filters applied: . Clear all
Page 1
Bone metastases.
Coleman RE, Croucher PI, Padhani AR, Clézardin P, Chow E, Fallon M, Guise T, Colangeli S, Capanna R, Costa L. Coleman RE, et al. Among authors: costa l. Nat Rev Dis Primers. 2020 Oct 15;6(1):83. doi: 10.1038/s41572-020-00216-3. Nat Rev Dis Primers. 2020. PMID: 33060614 Review.
Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H. Henry DH, et al. Among authors: costa l. J Clin Oncol. 2011 Mar 20;29(9):1125-32. doi: 10.1200/JCO.2010.31.3304. Epub 2011 Feb 22. J Clin Oncol. 2011. PMID: 21343556 Clinical Trial.
Therapeutic targeting of PD-1/PD-L1 blockade by novel small-molecule inhibitors recruits cytotoxic T cells into solid tumor microenvironment.
Acúrcio RC, Pozzi S, Carreira B, Pojo M, Gómez-Cebrián N, Casimiro S, Fernandes A, Barateiro A, Farricha V, Brito J, Leandro AP, Salvador JAR, Graça L, Puchades-Carrasco L, Costa L, Satchi-Fainaro R, Guedes RC, Florindo HF. Acúrcio RC, et al. Among authors: costa l. J Immunother Cancer. 2022 Jul;10(7):e004695. doi: 10.1136/jitc-2022-004695. J Immunother Cancer. 2022. PMID: 35863821 Free PMC article.
Bone Health in Metastatic Cancer.
Ventura C, Núñez SV, Gonçalves A, Abreu C, Costa L. Ventura C, et al. Among authors: costa l. Semin Oncol Nurs. 2022 Apr;38(2):151278. doi: 10.1016/j.soncn.2022.151278. Epub 2022 Apr 15. Semin Oncol Nurs. 2022. PMID: 35431084 Review.
Mid-infrared cross-comb spectroscopy.
Liu M, Gray RM, Costa L, Markus CR, Roy A, Marandi A. Liu M, et al. Among authors: costa l. Nat Commun. 2023 Feb 24;14(1):1044. doi: 10.1038/s41467-023-36811-7. Nat Commun. 2023. PMID: 36828826 Free PMC article.
The Roadmap of RANKL/RANK Pathway in Cancer.
Casimiro S, Vilhais G, Gomes I, Costa L. Casimiro S, et al. Among authors: costa l. Cells. 2021 Aug 4;10(8):1978. doi: 10.3390/cells10081978. Cells. 2021. PMID: 34440747 Free PMC article. Review.
315 results